A Unified Development Blueprint: Aligning Scientific Expertise To Accelerate Complex Biologics Programs

Developing today's increasingly complex biologics requires more than simply accelerating individual development activities. Traditional platform-based approaches often struggle with non-standard antibody formats, creating disconnects that can delay development and complicate scale-up.

This case study shows how Asimov and LOTTE Biologics addressed these challenges through an integrated development strategy that aligned scientific and manufacturing activities from the outset. By enabling earlier process understanding and parallel execution, the collaboration reduced development bottlenecks while advancing a complex antibody program from transfection to drug substance bulk fill in approximately 8.5 months. Discover how a more coordinated approach can improve manufacturability, reduce development risk, and help complex biologics programs reach critical milestones faster.

Download the full case study to explore the strategies behind a faster, more integrated path to biologics development.